Seattle, WA, United States of America

Thomas R Bukowski

USPTO Granted Patents = 32 


 

Average Co-Inventor Count = 6.7

ph-index = 17

Forward Citations = 572(Granted Patents)


Company Filing History:


Years Active: 1999-2016

Loading Chart...
Loading Chart...
Loading Chart...
32 patents (USPTO):Explore Patents

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide information on inventor Thomas R Bukowski.

Title: The Innovative Journey of Thomas R Bukowski

Introduction: Thomas R Bukowski, a prolific inventor based in Seattle, WA (US), has made significant contributions to the field of biotechnology and pharmaceuticals with a remarkable portfolio of 32 patents.

Latest Patents: Thomas R Bukowski's latest patents include Mutants of IL-29, where he has created homogeneous preparations of IL-28A, IL-28B, and IL-29 through the strategic mutation of cysteine residues in the polynucleotide sequences encoding these proteins. These mutations enable the proteins to bind to their receptors effectively, showcasing notable biological activities such as antiviral effects.

Career Highlights: Thomas R Bukowski is associated with ZymoGenetics, Inc., a prominent biotechnology company known for its groundbreaking research and development in the healthcare industry. His commitment to innovation and scientific excellence has led to the successful filing of numerous patents that have significantly advanced the field of biopharmaceuticals.

Collaborations: Throughout his career, Thomas R Bukowski has collaborated closely with esteemed colleagues such as Paul O Sheppard and Lowell J Brady. These collaborations have fostered a dynamic research environment that has facilitated the creation of cutting-edge solutions in the realm of biotechnology.

Conclusion: Thomas R Bukowski's groundbreaking work and dedication to innovation underscore his status as a pioneering inventor in the biotechnology sector. His significant contributions continue to drive advancements in the field, benefiting both the scientific community and society at large.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…